Looking Ahead in Oncology

We’ve been wondering – if CAR T-cell therapy, which is potentially curative in the liquid tumor space, proves effective in solid tumors as well, what does this mean for the targeted therapies and immuno-oncology agents which are currently dominating the treatment landscape in solid tumors?

Join KMK’s Market Research Principal, Lisa Logan, and a group of oncology experts while they discuss the possibilities of CAR T-cell therapy expansion to treat solid tumors as well as the implications on the current and future landscape of treatments across tumor types.
We’ll answer questions such as:
  • How will treaters trade-off the sky-high costs and logistical obstacles of CAR T-cell therapy with the familiarity, “simplicity” and relatively lower-priced treatments they are currently using for solid tumors?
  • What could this mean for other emerging cell and gene therapies (i.e., TIL, TCR, NK) in the coming years?


May 19 2021


12:30 pm

Local Time

  • Timezone: America/New_York
  • Date: May 19 2021
  • Time: 11:30 am
View Now